Compare Immunovant Inc. Common Stock (IMVT) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs 3M Company — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while 3M Company trades at $163.61 (market cap $83.61B). The key difference: 3M Company is far larger — about 12.6× Immunovant Inc. Common Stock's market cap, and 3M Company pays a 1.92% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and 3M Company for 169 Days on average.
| IMVT | MMM | |
|---|---|---|
Market Cap | $6.62B | $83.61B |
Volume | 1,131,364 | 3,188,723 |
Sector | Health | Industrials |
52-Week High | $44.96 | $183.79 |
52-Week Low | $17.03 | $141.10 |
Typical Hold Time | 0 Days | 169 Days |
Enterprise Value | $5.72B | $92.83B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MMM trades at $162.12, down 0.93% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.40, exceeding expectations, and maintains a robust net income margin of 11.9%. Analyst consensus is mixed with a $191 price target, while recent news highlights operational turnaround progress and litigation management.
The outlook balances solid fundamentals against high debt and weak consumer demand. Upside potential exists from industrial strength and shareholder returns, but risks include cost pressures and macroeconomic headwinds. The stock's current valuation at a P/E of 28.8 requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
